This is a routine new-hire equity grant with negligible dilution. No trading action warranted; monitor for any future updates on clinical or commercial progress for Amtagvi.
IOVA drugs
IOVA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 22 $4.06entry
- T+1 · 5mo ago +9.36%α +10.81% · $4.44
- T+5 · 5mo ago +4.68%α +6.75% · $4.25
- T+20 · 4mo ago +23.15%α +23.30% · $5.00
- T+60 · 2mo ago +130.54%α +128.80% · $9.36
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Iovance Biotherapeutics granted inducement stock options covering 140,860 shares to 27 new non-executive employees under its 2021 Inducement Plan, with an exercise price of $3.91 per share and a three-year vesting schedule. This is a routine equity grant to attract new hires and has no material impact on the company's financials or operations.
Key Facts
- Granted inducement stock options for 140,860 shares to 27 new non-executive employees.
- Exercise price set at $3.91, the closing price on June 18, 2026.
- Options vest over three years: one-third on first anniversary, remainder in quarterly installments.
- Granted under Iovance's Amended and Restated 2021 Inducement Plan per Nasdaq Listing Rule 5635(c)(4).
Financial Impact
140,860 shares represent approximately 0.1% of outstanding shares (based on ~140M shares outstanding); no material financial impact.
Risk Factors
- Minimal dilution from option exercises if stock price appreciates.
- No impact on near-term revenue or pipeline catalysts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3314899 |
Track record
21 reports on IOVA
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
- Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
- Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers